Acamprosate Initiated During Alcohol Detoxification
Completed · Phase 2 · Has a placebo group
Conditions studied: Alcohol Use Disorder
In brief
Acamprosate is approved by the Food and Drug Administration (FDA) for the treatment of alcoholism. The purpose of this study is to see if initiating acamprosate early in alcohol detoxification instead of waiting until detoxification has been completed effects the course of detoxification, adverse events during detoxification, drop out rate during the rehabilitative treatment phase, or overall efficacy of acamprosate for those with alcohol dependence who plan to receive at least two months of rehabilitative pharmacotherapy with acamprosate.
Key facts
- Study ID
- NCT00360594
- Run by
- Forest Laboratories
- People needed
- 40
- Starts
- 2006-10-01
- Expected to finish
- 2007-11-01
- Last updated by the study team
- 2017-01-11
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Treatment Research Center — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.